Stock · RMD · Healthcare
United States · Large Cap · listed since 1995 · Revenue 12 mo. $5.7B
Price as of 11/06/2026
ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally.
ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software. The company offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. It also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Original text from the data provider
Summary
59.1 of 100
Mean of the six area values. Each area value is the mean of the stock's ranks among the companies in its sector. 50 is the middle of the sector, not a share of companies beaten.
Analysis
What the price requires
If free cash flow stays at €1.5B (2026), it supports €16.4B. The remaining €12.9B of the market value assume it grows 8.1% a year for 10 years and not at all afterwards.
Required FCF growth per year
8.1%
no growth afterwards
with respect to the priced-in expectation
with respect to the priced-in expectation
No anomaly in the stored figures.
Since the last quarter
Q1 → Q2 2026
4 more unchanged: Revenue, 12 mo., Gross margin, EBIT margin, Return on equity
Derivation
Each area value is the average of its metrics' ranks within the sector (0 to 100, 50 is the middle). For metrics where lower is better, the rank is mirrored. The overall value is the average of the area values.
Price as of 11/06/2026.
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Return on equity | 23.13% | 11.52% | Rank 82 |
| Return on capital (Greenblatt) | 52.08% | 32.55% | Rank 70 |
| EBIT margin | 33.76% | 18.31% | Rank 91 |
| FCF margin | 29.18% | 14.12% | Rank 92 |
| Gross margin | 61.06% | 60.99% | Rank 50 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Revenue growth, 1 year | 9.85% | 8.04% | Rank 60 |
| Earnings growth, 3 years per year | 19.66% | 5.44% | Rank 76 |
| Earnings growth, 5 years per year | 26.34% | 7.00% | Rank 90 |
| Sustainable growth (ROE × retained earnings) | 2.76% | 3.66% | Rank 33 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Earnings yield | 4.43% | 2.90% | Rank 73 |
| FCF yield | 5.05% | 3.63% | Rank 72 |
| EV/saleslower is better | 5.67 | 4.03 | Rank 36 |
| EV/EBITlower is better | 16.78 | 21.73 | Rank 73 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Share price, 1 year | −15.35% | 8.66% | Rank 23 |
| Share price, 6 months | 14.29% | 24.27% | Rank 35 |
| Share price, 3 months | 16.15% | 15.42% | Rank 51 |
| Distance from 52-week high | −14.73% | −7.35% | Rank 31 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Accruals (Sloan)lower is better | 3.06% | 0.30% | Rank 28 |
| Change in share countlower is better | −0.87% | 0.00% | Rank 65 |
| Dividend streak in years | 13 | 10 | Rank 69 |
| Price reaction to results, market-adjusted | −7.45% | 0.05% | Rank 5 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Equity ratio | 73.45% | 48.40% | Rank 83 |
| Net debt/EBITDAlower is better | −0.30 | 1.11 | Rank 73 |
| Debt to equitylower is better | 0.13 | 0.48 | Rank 77 |
| Volatility, 1 yearlower is better | 30.17% | 31.42% | Rank 59 |
Ten years in figures
| Year | Revenue, $B | EBIT margin | FCF | Shares | Net debt |
|---|---|---|---|---|---|
| 2017 | 2.1 | 20.6% | $342.6M | 142M | $256.7M |
| 2018 | 2.3 | 23.2% | $433.6M | 144M | $92.8M |
| 2019 | 2.6 | 22.2% | $381.7M | 144M | $1.1B |
| 2020 | 3.0 | 27.4% | $696.3M | 146M | $836.1M |
| 2021 | 3.2 | 28.3% | $619.9M | 146M | $498.4M |
| 2022 | 3.6 | 28.0% | $195.1M | 147M | $643.8M |
| 2023 | 4.2 | 26.8% | $559.3M | 147M | $1.4B |
| 2024 | 4.7 | 28.2% | $1.3B | 148M | $635.6M |
| 2025 | 5.1 | 32.8% | $1.7B | 147M | −$357.6M |
| 2026 | 5.7 | 33.8% | $1.6B | 146M | −$643.3M |
5 of 7 StockScorer Score rules met · How the score is built
ResMed Inc mainly meets criteria in the Profitability category. Result from 18 strategies checked.
ResMed Inc is rated here with the StockScorer Score strategy, the flagship rule set. It compares return and cash-flow metrics with the median of the company's own sector and checks growth and price trend.
5 of 7 rules met
8 of 11 points
Detail data
Excerpt from 18 strategies checked. The full evaluation is visible after a free sign-up.
With a free account, you can see the match across all strategies checked in one complete overview.
Selected fundamental metrics for ResMed Inc.
| Metric | Stock | Sector |
|---|---|---|
| P/E ratio | 22.6 | 30.0 |
| P/B ratio | 5.2 | 4.8 |
| Return on equity (ROE) | 23.1% | 11.5% |
| Equity ratio | 73.4% | 48.4% |
| Debt-to-equity (D/E) | 0.13 | 0.48 |
| Dividend yield | 1.0% | 1.3% |
How comparable stocks in the same sector score in the StockScorer model.
| Symbol | Company | Rating |
|---|---|---|
| RMD | ResMed Incthis page | |
| WST | West Pharmaceutical Services Inc | Low3.6 |
| MDLN | Medline Inc. Class A Common Stock | locked |
| SOLV | Solventum Corp. | Low3.6 |
| BAX | Baxter International Inc | locked |
| RGEN | Repligen Corporation | locked |
Signed up in 30 seconds, free.
Learn more about the metrics in the metrics glossary or all rated stocks in the stock overview.
How StockScorer rates every stock is explained on the methodology page.